Factors associated with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis : a meta-analysis
Copyright: © 2020 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES..
BACKGROUND: Patients with cardiac sarcoidosis (CS) are at increased risk of atrioventricular blocks, ventricular arrhythmias, and sudden cardiac death. Objectives We aimed to investigate the characteristics associated with appropriate therapy in implantable cardiac defibrillator (ICD) -implanted CS patients.
METHODS: We performed a PubMed and Web of Science search for studies reporting patients with CS who underwent an ICD implantation. The primary criterion was an appropriate therapy.
RESULTS: We screened 705 studies, of which 5 were included in the final analysis. We conducted a meta-analysis including 464 patients (mean age 55 years, 282 males (60%)). The mean follow-up was 3.5 years. Among the 464 patients, 180 received an appropriate therapy (39%). Patients who received an appropriate therapy were younger (-3.33, 95% confidence interval (CI) -6.42 to -0.23, p=0.004), were more likely to be male (OR 2.06, 95% CI 1.37-3.09, p=0.0005), had a lower left ventricular ejection fraction (LVEF) (-10.5, 95% CI -18.23 to -2.78, p=0.008), had a higher rate of complete heart block (OR 2.19, 95% CI 1.20 to 3.99, p=0.01), and more frequently had ventricular pacing (OR 6.44 95% CI 2.57 to 16.16, p<0.0001).
CONCLUSIONS: Appropriate ICD therapy during CS is associated with young age, male sex, low LVEF, history of complete heart block, and ventricular pacing. (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (1): 17-23).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG - 37(2020), 1 vom: 16., Seite 17-23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Azoulay, Levi-Dan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiac sarcoidosis |
|---|
| Anmerkungen: |
Date Completed 03.11.2020 Date Revised 17.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.36141/svdld.v37i1.8271 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316626546 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316626546 | ||
| 003 | DE-627 | ||
| 005 | 20231225161509.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.36141/svdld.v37i1.8271 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316626546 | ||
| 035 | |a (NLM)33093765 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Azoulay, Levi-Dan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Factors associated with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis |b a meta-analysis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.11.2020 | ||
| 500 | |a Date Revised 17.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © 2020 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES. | ||
| 520 | |a BACKGROUND: Patients with cardiac sarcoidosis (CS) are at increased risk of atrioventricular blocks, ventricular arrhythmias, and sudden cardiac death. Objectives We aimed to investigate the characteristics associated with appropriate therapy in implantable cardiac defibrillator (ICD) -implanted CS patients | ||
| 520 | |a METHODS: We performed a PubMed and Web of Science search for studies reporting patients with CS who underwent an ICD implantation. The primary criterion was an appropriate therapy | ||
| 520 | |a RESULTS: We screened 705 studies, of which 5 were included in the final analysis. We conducted a meta-analysis including 464 patients (mean age 55 years, 282 males (60%)). The mean follow-up was 3.5 years. Among the 464 patients, 180 received an appropriate therapy (39%). Patients who received an appropriate therapy were younger (-3.33, 95% confidence interval (CI) -6.42 to -0.23, p=0.004), were more likely to be male (OR 2.06, 95% CI 1.37-3.09, p=0.0005), had a lower left ventricular ejection fraction (LVEF) (-10.5, 95% CI -18.23 to -2.78, p=0.008), had a higher rate of complete heart block (OR 2.19, 95% CI 1.20 to 3.99, p=0.01), and more frequently had ventricular pacing (OR 6.44 95% CI 2.57 to 16.16, p<0.0001) | ||
| 520 | |a CONCLUSIONS: Appropriate ICD therapy during CS is associated with young age, male sex, low LVEF, history of complete heart block, and ventricular pacing. (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (1): 17-23) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cardiac sarcoidosis | |
| 650 | 4 | |a complete heart block | |
| 650 | 4 | |a implantable cardioverter defibrillator | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a sudden death | |
| 700 | 1 | |a Waintraub, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Haroche, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Amoura, Zahir |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen Aubart, Fleur |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG |d 1996 |g 37(2020), 1 vom: 16., Seite 17-23 |w (DE-627)NLM088329399 |x 1124-0490 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:1 |g day:16 |g pages:17-23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.36141/svdld.v37i1.8271 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 1 |b 16 |h 17-23 | ||